This study provides robust evidence supporting the use of SGLT2 inhibitors in heart failure with preserved ejection fraction. Long-term outcomes data would further strengthen these findings. - https://www.ssrd.ch/ordentliche-mitglieder.html , Timely discussion on the cardiovascular safety of tyrosine kinase inhibitors in oncology. Cardio-oncology collaboration is increasingly vital. .